 Given the early clinical data on Checkmate Pharmaceuticals Incs NASDAQ:CMPI vidutolimod, key opinion leaders remain positively biased on its outlook, according to BofA Securities. The Checkmate Pharmaceuticals Analyst: Jason Zemansky upgraded Checkmate Pharmaceuticals from Neutral to Buy and lowered the price target from 19 to 7. 